Regenxbio Q4 2023 GAAP EPS $(1.43) Misses $(1.27) Estimate, Sales $22.21M Miss $34.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Regenxbio (NASDAQ:RGNX) reported Q4 2023 earnings with a GAAP EPS of $(1.43), missing the $(1.27) estimate, and sales of $22.21M, missing the $34.00M estimate. This represents a 29.13% decrease in sales compared to the same period last year.
February 27, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regenxbio reported a significant miss in both EPS and sales for Q4 2023, with a 29.13% decrease in sales compared to the same period last year.
The significant miss in both EPS and sales estimates, coupled with a notable year-over-year decrease in sales, is likely to negatively impact investor sentiment and could lead to a short-term decrease in RGNX's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100